LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen

BACKGROUND: Casirivimab and imdevimab (CAS/IMDEV) is authorized for emergency use in the US for outpatients with COVID-19. We present results from patient cohorts receiving low flow or no supplemental oxygen at baseline from a phase 1/2/3, randomized, double-blinded, placebo (PBO)-controlled trial o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mylonakis, Eleftherios, Somersan-Karakaya, Selin, Sivapalasingam, Sumathi, Ali, Shazia, Sun, Yiping, Bhore, Rafia, Mei, Jingning, Miller, Jutta, Cupelli, Lisa, Hooper, Andrea T, Hamilton, Jennifer D, Pan, Cynthia, Pham, Viet, Zhao, Yuming, Hosain, Romana, Mahmood, Adnan, Davis, John D, Turner, Kenneth C, Kim, Yunji, Cook, Amanda, Menon, Vidya, Wells, Jason C, Kowal, Bari, Soo, Yuhwen, DiCioccio, A Thomas, Geba, Gregory P, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D, Weinreich, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644229/
http://dx.doi.org/10.1093/ofid/ofab466.1645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644229/
http://dx.doi.org/10.1093/ofid/ofab466.1645

Ejemplares similares